Investors of PROCEPT BioRobotics Can Now Pursue Securities Fraud Class Action Lawsuit

Class Action Lawsuit Against PROCEPT BioRobotics Corporation

Investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) may be facing a significant opportunity as a class action lawsuit has been filed alleging securities fraud. Specifically, this lawsuit will represent those who purchased or otherwise acquired common stock of PROCEPT between February 28, 2024, and February 25, 2026.

What You Need to Know:

The lawsuit, which has been initiated by the law firm Kessler Topaz Meltzer & Check, LLP, highlights serious allegations against the company. Affected investors are encouraged to understand the circumstances surrounding the legal action, the potential claims, and the process to become involved. The deadline for filing to seek lead plaintiff status in this case is September 22, 2026.

Details of the Case

The class action lawsuit has been filed in the United States District Court for the Northern District of California. The case is specifically noted as Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, No. 26-cv-07691 (N.D. Cal.). Investors within the specified time frame are likely to be affected by the allegations reported in the complaint.

The core of these allegations is that the executives of PROCEPT made materially false statements regarding the demand for their product, which significantly misled investors about the company’s financial standing. A particular focus is placed on the Aquablation therapy system developed by PROCEPT for treating benign prostatic hyperplasia (BPH), more commonly known as an enlarged prostate.

Throughout the class period, the complaint alleges that PROCEPT officials failed to disclose that they implemented a discount program to boost sales by encouraging bulk orders. This tactic led to reported sales figures considerably higher than actual demand, thereby inflating stock prices artificially and leading to hidden financial risks for the company. The lawsuit contends that this created a facade of growth, misleading investors about the company’s true operational capability and potential for profitability.

The Impact of the Allegations on Stock Price

The ramifications of these disclosures became evident on February 25, 2026, when PROCEPT announced earnings that revealed a significant discrepancy—handpiece sales had consistently outpaced medical procedures for every quarter since the first fiscal quarter of 2023. This realization prompted a drastic response in the stock market, with PROCEPT's common stock dropping by over 18%, revealing the market’s negative reaction to the newly unveiled financial truths.

What Affected Investors Can Do

Investors who have purchased PROCEPT stock and believe they've incurred losses are encouraged to take action before the September 22 deadline. They may contact Kessler Topaz Meltzer & Check, LLP to discuss their legal rights and potential recovery options. The law firm operates on a contingency fee basis, meaning no up-front costs for victims of the alleged fraud.

An important aspect of class action lawsuits is the appointment of a lead plaintiff. In this context, the lead plaintiff will represent the interests of all affected investors, making decisions on behalf of the class, such as the selection of legal representation. Finally, investors who choose to participate in the lawsuit should be aware that any recovery they may receive in the future will not be influenced by their decision to serve as a lead plaintiff or remain an absent class member.

Conclusion

As more details unfold in this significant lawsuit, it underscores the crucial role of transparency in corporate governance and investor relations. Affected investors of PROCEPT BioRobotics are urged to stay informed and actively engage in legal discussions to safeguard their interests amidst these serious allegations. For comprehensive insights and updates about the case, affected individuals should monitor communications from their legal counsel closely.

For more information, affected parties can connect with Jonathan Naji, Esq., from Kessler Topaz Meltzer & Check, LLP, through email or phone. This important step may provide a pathway to recovering potential losses incurred due to the alleged fraud by PROCEPT BioRobotics Corporation.